← board
XTLB
TLC Biopharmaceuticals, Inc.distress 5/10 · elevated risk$2.920%today-64% from 52w high
Pain 1
Lead: Postsurgical Pain Management
Revenue
pre-revenue
Liquidity
$0M
Runway
0.1 yrs
Shares 1y
0%
Price & events
-30.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
-0.3%
1W
+8.1%
1M
+16.3%
3M
-30.5%
6M
-59.4%
1Y
-73.4%
2Y
-82.4%
5Y
-79.1%
All
Overview
- Market Cap
- $2.76B
- Volume
- 3.20K
- 52 Week Range
- $2.06 – $8.20
- Total Shares
- 946.24M
- Float Shares
- 1.50M
- Short %
- 0.51%
- % Held by Insiders
- 38.46%
- % Held by Institutions
- 3.08%
- RVOL
- 0.02x
- Beta
- 0.55
Pipeline stages · 1 programs
TLC590, Ropivacaine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-07-01 | Phase 2 | TLC590, Ropivacaine | Postsurgical Pain Management | — | recruiting |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 946,243,356 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — Postsurgical Pain Management
- none identified
Recent news
- 2026-07-22XTL Biopharmaceuticals Regains Nasdaq Compliance and Enters One-Year Monitoring Period - The Globe and Mail
- 2026-07-21XTL Biopharmaceuticals Regains Nasdaq Compliance and Enters One-Year Monitoring Period - TipRanks
- 2026-07-21XTL Biopharmaceuticals (XTLB) wins back Nasdaq listing, faces 1-year watch - Stock Titan
- 2026-07-08Enterprise value to EBIT forward of XTL Biopharmaceuticals Ltd. – TASE:XTLB - TradingView
- 2026-06-30XTL Biopharmaceuticals Completes Acquisition of Psyga Bio to Establish Psychedelic Biotechnology Platform - Quiver Quantitative
- 2026-06-30XTL Biopharmaceuticals (XTLB) Holds Steady at $2.36 as Trading Range Tightens - VOLD Alert - dars.gov.et
- 2026-06-30XTL Biopharmaceuticals (XTLB) Holds Steady at $2.36 as Trading Range Tightens - Dealer Delta - dars.gov.et
- 2026-06-29XTL Biopharmaceuticals Ltd. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.